Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study

doi:10.5306/wjco.124416

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Sep 24, 2026; 17(9): 124416
Published online Sep 24, 2026. doi: 10.5306/wjco.124416

Table 3 Summary of grade ≥ 3 adverse events

Event, n	Anti-PD-1 plus cetuximab (n = 11)	Anti-PD-1 plus anlotinib (n = 10)
Tumor pain	1	5
Decreased appetite	2	3
Tumor hemorrhage	1	2
Hypertension	0	3
Hypokalemia	0	1
Rash	1	1
Pneumonia	0	1
Diarrhea	0	1
Ascites	1	0

PD-1: Programmed cell death 1.

Full Size Table

Citation: Wang JX, Wang TX, Song YT, Xu GH, Zhang YB, Zhang B. Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study. World J Clin Oncol 2026; 17(9): 124416
URL: https://www.wjgnet.com/2218-4333/full/v17/i9/124416.htm
DOI: https://dx.doi.org/10.5306/wjco.124416

Wang JX, Wang TX, Song YT, Xu GH, Zhang YB, Zhang B. Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study. World J Clin Oncol 2026; 17(9): 124416 [DOI: 10.5306/wjco.124416]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.